Patents Examined by Brian Gangle
-
Patent number: 11977068Abstract: A method for testing ecotoxicity of disinfection by-products (DBPs) is disclosed, including the following steps: firstly, hatching and culturing a brine shrimp to obtain a second-instar brine shrimp larvae; secondly, putting the brine shrimp larvae into a water sample containing the DBPs, obtaining a survival rate through acute toxicity exposure and chronic toxicity exposure, respectively, to calculate the toxicity of the water sample to brine shrimp. The new method includes both acute and chronic toxicity tests. The test water sample can be either a single substance solution or an actual disinfection water sample. The brine shrimp has high sensitivity and is convenient to hatch and culture. The raw materials are inexpensive and easily available. The requirements for the culture environment are not high, and the toxicity end-point is clear. The new method is simple, sensitive and economical, and therefore, a popularization is feasible in sewage and reuse water plants.Type: GrantFiled: January 14, 2021Date of Patent: May 7, 2024Assignee: TONGJI UNIVERSITYInventors: Wenhai Chu, Zuxin Xu, Xinmiao Luan
-
Patent number: 11970526Abstract: Provided are various embodiments relating to interleukin 13 receptor subunit alpha-1/interleukin 4 receptor subunit alpha (IL13R/IL4R) contiguous polypeptides derived from companion animal species and that bind to IL13 and/or IL4. Such contiguous polypeptides can be used in methods to treat IL13 and/or IL4-induced conditions in companion animals, such as canines, felines, and equines.Type: GrantFiled: April 20, 2018Date of Patent: April 30, 2024Assignee: Elanco US Inc.Inventors: Hangjun Zhan, Lam Nguyen, Fawn Qian, Shyr Jiann Li
-
Patent number: 11969474Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.Type: GrantFiled: May 7, 2018Date of Patent: April 30, 2024Assignee: Wyeth LLCInventor: A. Krishna Prasad
-
Patent number: 11969445Abstract: A method and system for modulating an individual's microbiome in a manner such that individuals who are overweight, obese and/or suffer from cardiometabolic diseases and/or inflammatory bowel diseases are able to reduce the incidence of chronic conditions and diseases associated therewith. Certain embodiments are directed to a method and bacterial formulations for reducing the likelihood of developing NAFLD and NASH.Type: GrantFiled: August 11, 2023Date of Patent: April 30, 2024Assignee: Seed Health, Inc.Inventor: Joseph E. Kovarik
-
Patent number: 11965029Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.Type: GrantFiled: June 4, 2021Date of Patent: April 23, 2024Assignee: Amgen Inc.Inventors: Dirk E. Smith, Ian Foltz, Chadwick T. King, Ai Ching Lim, Rutilio Clark, Michael R. Comeau, Randal R. Ketchem, Donghui Shi, Xiaoshan Min, Zhulun Wang
-
Patent number: 11965017Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a whey acidic protein (WAP) domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: October 8, 2020Date of Patent: April 23, 2024Assignee: InhibRx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Patent number: 11957751Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: February 12, 2021Date of Patent: April 16, 2024Assignee: Ludwig Institute for Cancer Research, Ltd.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 11959066Abstract: A Pseudomonas monteilii strain with salinity-alkalinity tolerance is provided. The strain is Pseudomonas monteilii 9-2, which has been deposited in China General Microbiological Culture Collection Center (CGMCC) on Oct. 25, 2021, with an accession number of CGMCC No. 23666; and an internal transcribed spacer (ITS) sequence is shown in SEQ ID NO: 1. This application further provides an application of the Pseudomonas monteilii strain in the degradation of petroleum hydrocarbons in a saline-alkali environment.Type: GrantFiled: January 4, 2023Date of Patent: April 16, 2024Assignee: Northwest Institute of Eco-Environment and Resources, CASInventors: Yingqin Wu, Zhiyu Wang, Tong Wang, Longmiao Yuan, Yanhong Liu, Rong Ma
-
Patent number: 11957740Abstract: Compositions comprising the L complex or the M complex of the botulinum neurotoxin E with its associated neurotoxin binding protein(s) (NBP), methods of making, and methods of use to treat pain and wrinkles by injecting locally. Methods of making and isolating the L and M complex comprise a multi-step process of: providing a bacterial cultured media comprising the complex of botulinum neurotoxin E and neurotoxin binding proteins; centrifuging and pelletizing the cultured media; stirring the pelletized culture at 0 to 10° C. over a period of 4 to 24 hours; centrifuging the stirred solution to obtain a supernatant; precipitating the supernatant and filtering to obtain the precipitate; and dissolving the precipitate, centrifuging and filtering to obtain a solution comprising M complex and/or L complex of botulinum neurotoxin E and its NBP; and passing the solution through a functionalized sephadex ion exchange column to isolate the complex.Type: GrantFiled: March 13, 2021Date of Patent: April 16, 2024Assignee: Prime Bio, Inc.Inventors: Bal Ram Singh, Raj Kumar
-
Patent number: 11951140Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.Type: GrantFiled: May 4, 2023Date of Patent: April 9, 2024Assignee: Seed Health, Inc.Inventors: Tye Jensen, Joseph E. Kovarik
-
Patent number: 11951207Abstract: The present invention provides a stable liquid pharmaceutical formulation containing: an antibody or its antigen-binding fragment; a surfactant; a sugar or its derivative; and a buffer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity while containing a high content of the antibody, has excellent long-term storage stability based on excellent stability under accelerated conditions and severe conditions, and may be administered subcutaneously.Type: GrantFiled: June 28, 2017Date of Patent: April 9, 2024Assignee: Celltrion Inc.Inventors: Joon Won Lee, Won Yong Han, Su Jung Kim, Jun Seok Oh, So Young Kim, Su Hyeon Hong, Yeon Kyeong Shin
-
Patent number: 11953503Abstract: Provided is a universal method for quantitatively determining therapeutic tumor necrosis factor (TNF)-alpha inhibitors in patient samples that is sufficiently sensitive for being able to detect all therapeutic TNF-alpha inhibitors.Type: GrantFiled: January 14, 2019Date of Patent: April 9, 2024Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Harald Althaus, Thorsten Keller
-
Patent number: 11952576Abstract: A novel method of diluting the structures in the cell population, such that individual cells, dependent on the activity of the structures, become single measurement devices. This can be applied to all Bacterial Microcomparments (“BMCs”), organelles, and macromolecules, and could provide a universal method for the design of novel ones and understanding of the diverse structures. In one aspect the present invention provides A method of creating a bacterial strain with inducible and detectable carboxysomes. The method includes the steps of incorporating a labeled carbon-fixation enzyme into the genome of a bacterium; deleting all or a portion of the ccm operon from the bacterium; and reintroducing a ccm operon comprising an inducible promoter to create a ?ccm+ strain.Type: GrantFiled: November 16, 2020Date of Patent: April 9, 2024Assignee: The Regents of the University of Colorado, a body corporateInventors: Jeffrey Carlyle Cameron, Nicholas C. Hill, Jian Wei Tay, Sabina Altus, David Matthew Bortz, Kristin Ann Moore
-
Patent number: 11952597Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.Type: GrantFiled: July 7, 2020Date of Patent: April 9, 2024Assignee: Pfizer Inc.Inventors: Jason Arnold Lotvin, Annaliesa Sybil Anderson, Robert G. K. Donald, Michael James Flint, Narender Kumar Kalyan, Kathrin Ute Jansen, Maninder K. Sidhu, Justin Keith Moran, Mark Edward Ruppen, Weiqiang Sun
-
Patent number: 11951139Abstract: Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.Type: GrantFiled: August 23, 2022Date of Patent: April 9, 2024Assignee: Seed Health, Inc.Inventor: Joseph E. Kovarik
-
Patent number: 11944675Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: GrantFiled: October 2, 2020Date of Patent: April 2, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Fabiana Fernandez, Michael Kowarik, Michael Wacker, Michael Wetter
-
Patent number: 11946927Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.Type: GrantFiled: August 20, 2019Date of Patent: April 2, 2024Inventors: Bruce R. Yacyshyn, Mary E. Yacyshyn
-
Patent number: 11938179Abstract: Disclosed herein are methods and compositions for treating or preventing bacterial infection. In particular, the methods and compositions are directed towards C. difficile infection. In particular aspects, the compositions are vaccines containing multimeric polypeptides containing portions of multiple toxins from bacteria. The polypeptides induce effective immune responses thus treating or preventing infection.Type: GrantFiled: August 10, 2021Date of Patent: March 26, 2024Assignee: Novavax, Inc.Inventors: Jing-Hui Tian, Ye Liu, Gale Smith, Gregory Glenn, David Flyer
-
Patent number: 11939592Abstract: An object of the present invention is to provide a recombinant phage having high safety and excellent practicality and usefulness. Provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a bacteriophage genome in which a part of a virion constituent gene is deleted is stored in a head, and a method for preparing the same. In addition, provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a plasmid having a packaging site and encoding a target gene is stored in a head, and a method for preparing the same.Type: GrantFiled: December 5, 2019Date of Patent: March 26, 2024Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEMInventors: Shoichi Mitsunaka, Hiroki Ando
-
Patent number: 11939396Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.Type: GrantFiled: June 30, 2020Date of Patent: March 26, 2024Assignee: Genentech, Inc.Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi